Switch theme
Sign up to access all valuation multiples
Yantai Dongcheng Biochemicals Co Ltd is a biochemical analytical profile index (API) manufacturers in China. In addition, the company also focuses on the development of finished preparation which covers the therapeutic area of cardiovascular, oncology, orthopedics, and anti-infection. Its product offering includes heparin sodium, chondroitin sulfate, marine collagen, hyaluronic acid, glucosamine, heparinoids, and cytochrome C. The company's API products have been exported to more than fifty countries and regions, including the United States of America, Germany, Austria, and Japan.
1998
n/a
LTM Revenue $406M
Last FY EBITDA $67.1M
$1.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Yantai Dongcheng has a last 12-month revenue (LTM) of $406M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Yantai Dongcheng achieved revenue of $400M and an EBITDA of $67.1M.
Yantai Dongcheng expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Yantai Dongcheng valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $406M | XXX | $400M | XXX | XXX | XXX |
| Gross Profit | $193M | XXX | $189M | XXX | XXX | XXX |
| Gross Margin | 47% | XXX | 47% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | $67.1M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 17% | XXX | XXX | XXX |
| EBIT | $41.7M | XXX | $57.5M | XXX | XXX | XXX |
| EBIT Margin | 10% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $28.9M | XXX | $25.7M | XXX | XXX | XXX |
| Net Margin | 7% | XXX | 6% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Yantai Dongcheng's stock price is CNY 15 (or $2).
Yantai Dongcheng has current market cap of CNY 12.0B (or $1.7B), and EV of CNY 11.9B (or $1.7B).
See Yantai Dongcheng trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.7B | $1.7B | XXX | XXX | XXX | XXX | $0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Yantai Dongcheng has market cap of $1.7B and EV of $1.7B.
Yantai Dongcheng's trades at 4.2x EV/Revenue multiple, and 24.8x EV/EBITDA.
Equity research analysts estimate Yantai Dongcheng's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Yantai Dongcheng has a P/E ratio of 57.8x.
See valuation multiples for Yantai Dongcheng and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.7B | XXX | $1.7B | XXX | XXX | XXX |
| EV (current) | $1.7B | XXX | $1.7B | XXX | XXX | XXX |
| EV/Revenue | 4.1x | XXX | 4.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 24.8x | XXX | XXX | XXX |
| EV/EBIT | 40.0x | XXX | 29.0x | XXX | XXX | XXX |
| EV/Gross Profit | 8.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 57.8x | XXX | 65.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -70.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialYantai Dongcheng's last 12 month revenue growth is 8%
Yantai Dongcheng's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Yantai Dongcheng's rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Yantai Dongcheng's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Yantai Dongcheng and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 24% | XXX | 25% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 33% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Yantai Dongcheng acquired XXX companies to date.
Last acquisition by Yantai Dongcheng was XXXXXXXX, XXXXX XXXXX XXXXXX . Yantai Dongcheng acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Yantai Dongcheng founded? | Yantai Dongcheng was founded in 1998. |
| Where is Yantai Dongcheng headquartered? | Yantai Dongcheng is headquartered in China. |
| Is Yantai Dongcheng publicy listed? | Yes, Yantai Dongcheng is a public company listed on SHE. |
| What is the stock symbol of Yantai Dongcheng? | Yantai Dongcheng trades under 002675 ticker. |
| When did Yantai Dongcheng go public? | Yantai Dongcheng went public in 2012. |
| Who are competitors of Yantai Dongcheng? | Similar companies to Yantai Dongcheng include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Yantai Dongcheng? | Yantai Dongcheng's current market cap is $1.7B |
| What is the current revenue of Yantai Dongcheng? | Yantai Dongcheng's last 12 months revenue is $406M. |
| What is the current revenue growth of Yantai Dongcheng? | Yantai Dongcheng revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Yantai Dongcheng? | Current revenue multiple of Yantai Dongcheng is 4.1x. |
| Is Yantai Dongcheng profitable? | Yes, Yantai Dongcheng is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
